{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-24-000091","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.943519+00:00","generated_at":"2026-05-30T01:36:12.152035+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Exagen Q3 revenue $12.5M (-7% YoY); ASP up 26%; net loss improves 37% YTD","bullets":["Q3 2024 revenue $12.5M, down from $13.4M in Q3 2023, impacted by $1.2M one-time adjustments.","AVISE CTD trailing twelve-month ASP $404, up 26% from $320 a year ago.","Net loss first nine months 2024 improved 37% to $11.4M from $18.1M; adj. EBITDA loss improved 42% to $7.6M.","Cash and equivalents $22.0M at Sept 30; net cash burn $2.5M in Q3.","Completed validation for new biomarkers, submitted to NY State; appointed Jeff Black as CFO effective Sept 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-24-000091","json":"https://secwatch.observer/filing/0001274737-24-000091.json","markdown":"https://secwatch.observer/filing/0001274737-24-000091.md","text":"https://secwatch.observer/filing/0001274737-24-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000091/0001274737-24-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000091/exdx-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:36:12.152035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}